Efficacy News and Research

RSS
CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Herbal supplement can become dangerous when taken with prescribed drugs

Herbal supplement can become dangerous when taken with prescribed drugs

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

Genetic variants alter chance of sunitinib dose reduction

Genetic variants alter chance of sunitinib dose reduction

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Novel method to measure neuron response to transcranial magnetic stimulation of the brain

Novel method to measure neuron response to transcranial magnetic stimulation of the brain

Light-sensitive molecule enables noninvasive silencing of neurons

Light-sensitive molecule enables noninvasive silencing of neurons

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

New research project aims to tackle antibiotic resistance with inhalable nanotherapeutics

New research project aims to tackle antibiotic resistance with inhalable nanotherapeutics

Newly identified compound may halt progression of Alzheimer's disease

Newly identified compound may halt progression of Alzheimer's disease

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Researchers identify two classes of anti-depressants that reduce symptoms of depression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.